Table 4.

Predictive factors for TCZ discontinuation in CDAI50 responders entering the second treatment year

	Cox regression model		Fine-Gray regression model
	Adjusted HR (95% CI)	P value	Adjusted HR (95% CI)	P value
Due to secondary loss of efficiency
High and moderate CDAI at 12 months	2.35 (1.21, 4.54)	0.01	2.58 (1.41, 4.72)	0.002
High and moderate CDAI at 6 months	1.77 (1.07, 2.94)	0.03	—	—
Due to adverse events
Age per 1 year more	1.05 (1.02, 1.09)	0.01	1.04 (1.02, 1.08)	0.01

All confounders listed in the table were factors identified as true confounders and were included in the final regression model.

TCZ: tocilizumab; CDAI: clinical disease activity index; HR: hazard ratio.